GW Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
December 31 2018 - 7:00AM
GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the
Group), a biopharmaceutical company focused on discovering,
developing and commercializing novel therapeutics from its
proprietary cannabinoid product platform, announced that Justin
Gover, GW’s Chief Executive Officer, will present a company update
at the J.P. Morgan 2019 Healthcare Conference in San Francisco,
Calif. on Tuesday, January 8, 2019 at 7:30 a.m. PST (10:30 a.m.
EST), followed by a Q&A session.
A live audio webcast of the presentation will be
available through GW’s corporate website in the investor relations
section from the investor’s calendar of events page at
www.gwpharm.com. A replay will be available soon
after the live presentation.
About GW Pharmaceuticals plc and
Greenwich Biosciences, Inc.
Founded in 1998, GW is a biopharmaceutical
company focused on discovering, developing and commercializing
novel therapeutics from its proprietary cannabinoid product
platform in a broad range of disease areas. GW, along with its U.S.
subsidiary Greenwich Biosciences, has received U.S. FDA approval
for EPIDIOLEX (cannabidiol) oral solution for the treatment of
seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet
syndrome in patients two years of age or older and which is now
available by prescription in the U.S. The Company has submitted a
regulatory application in Europe for the adjunctive treatment of
seizures associated with LGS and Dravet syndrome. The company
continues to evaluate EPIDIOLEX in additional rare epilepsy
conditions and currently has an ongoing clinical trial in tuberous
sclerosis complex (TSC). GW commercialized the world’s first
plant-derived cannabinoid prescription drug, Sativex® (nabiximols),
which is approved for the treatment of spasticity due to multiple
sclerosis in numerous countries outside the United States and for
which the company is now planning a U.S. Phase 3 trial. The Company
has a deep pipeline of additional cannabinoid product candidates
which includes compounds in Phase 1 and 2 trials for epilepsy,
glioblastoma, and schizophrenia. For further information, please
visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc |
|
Stephen Schultz, VP Investor Relations |
917 280 2424 / 401 500 6570 |
|
|
|
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
GW Pharmaceuticals (NASDAQ:GWPH)
Historical Stock Chart
From Sep 2023 to Sep 2024